RP24-142A19.3 Inhibitors
RP24-142A19.3 inhibitors refers to a class of chemical compounds designed to interact with a specific molecular target identified by the alphanumeric code "RP24-142A19.3." This code is typically found in a genomic library or a specific notation system used to classify and reference particular sequences within a genome or a set of genetic constructs. The nomenclature suggests that this target may be a part of a larger sequence or identified through a particular mapping project, possibly relating to a chromosomal location. The inhibitors in this class would be molecules that are capable of binding to or interacting with the biological entity denoted by RP24-142A19.3 with high specificity, thereby altering its activity.
Chemical inhibitors such as those in the RP24-142A19.3 class are often small organic molecules, although they can also be peptides, peptidomimetics, or other types of biologically active compounds. The design and development of these inhibitors typically involve a process of identifying the active site or the binding region of the target and then crafting a molecule that can interact with this site in a way that modulates its function. This can involve hydrogen bonding, hydrophobic interactions, van der Waals forces, and other types of chemical interactions. The specificity and affinity of these inhibitors are paramount, as off-target effects can lead to unintended interactions with other molecular entities. The development process often involves iterative cycles of synthesis and testing to refine the inhibitor's properties, such as its stability, solubility, and specificity for the desired target.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, Wortmannin prevents the phosphorylation and activation of AKT, a downstream effector in the PI3K pathway. As RP24-142A19.3 is a protein that may be regulated by the PI3K pathway, inhibition of this pathway by Wortmannin can lead to decreased activity of RP24-142A19.3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another chemical that selectively inhibits PI3K. It competes with ATP for binding to the catalytic site of PI3K, thus preventing the activation of the PI3K/AKT signaling pathway. This action might result in diminished RP24-142A19.3 activity if it is downstream or regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), which is a part of the PI3K/AKT/mTOR pathway. By inhibiting mTOR, Rapamycin can lead to a decrease in protein synthesis and cell proliferation, which might indirectly reduce the functional activity of RP24-142A19.3 if it is regulated by mTOR activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of the extracellular signal-regulated kinase (ERK) pathway. By inhibiting MEK, PD98059 can suppress the activation of ERK and its downstream effects, potentially reducing the activity of RP24-142A19.3 if it is influenced by the ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the regulation of apoptosis and cell proliferation. Inhibition of JNK could lead to decreased activity of RP24-142A19.3 if it is linked to the JNK signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is involved in inflammatory responses and cell differentiation. By inhibiting p38, SB203580 might indirectly decrease RP24-142A19.3 activity if RP24-142A19.3 is associated with the p38 MAPK pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). ROCK is involved in various cellular functions, including contraction, motility, and proliferation. Inhibition of ROCK could therefore lead to decreased activity of RP24-142A19.3 if it is regulated by ROCK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1 and MEK2, preventing the activation of ERK1 and ERK2. This inhibitory action could result in reduced activity of RP24-142A19.3 if it operates within the MEK/ERK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 could impact various signaling pathways, including those regulating cell growth and differentiation, potentially affecting RP24-142A19.3 activity. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a selective inhibitor of the fibroblast growth factor receptor (FGFR) tyrosine kinase. It blocks the FGFR signaling pathway, which may reduce the activity of RP24-142A19.3 if it is influenced by FGFR signaling. | ||||||